{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:24:46Z","timestamp":1770992686710,"version":"3.50.1"},"reference-count":11,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":8343,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1995,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We compared the efficacy of two neuroleptics with different receptor profiles (zuclopenthixol and haloperidol) in learning disabled patients with behavioural disturbance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A double-blind crossover study (2\u00d78 weeks; <jats:italic>n<\/jats:italic> = 34), interrupted by a two-week single-blind washout period, was employed. Assessments included the Schedule for Handicaps, Behaviour, and Skills (SHBS) and Clinical Global Impression (CGI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The SHBS score was significantly reduced for the zuclopenthixol cohort only. End-point analysis between the two drugs also showed an enhanced effect for zuclopenthixol over haloperidol. CGI scores did not reveal significant differences between the two drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Zuclopenthixol may be superior to haloperidol for the treatment of behavioural disturbances in mentally retarded subjects.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.166.3.374","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T05:31:20Z","timestamp":1224048680000},"page":"374-377","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness of Zuclopenthixol Compared with Haloperidol in the Treatment of Behavioural Disturbances in Learning Disabled Patients"],"prefix":"10.1192","volume":"166","author":[{"given":"Ulrik F.","family":"Malt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Nystad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torkel","family":"Bache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Noren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Sjaastad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut Ove","family":"Solberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sverre","family":"T\u2298nseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Zachariassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"M\u00e6hlum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000183953_ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.149.3.373"},{"key":"S0007125000183953_ref9","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.86.2.420"},{"key":"S0007125000183953_ref11","volume-title":"The ICD\u201310 Classification of Mental and Behavioural Disorders","year":"1992"},{"key":"S0007125000183953_ref3","first-page":"217","article-title":"Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients","volume":"5","author":"Izmeth","year":"1988","journal-title":"Pharmatherapeutica"},{"key":"S0007125000183953_ref1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-8774-9"},{"key":"S0007125000183953_ref4","first-page":"39","article-title":"Neuroleptic treatment of oligophrenic patients","volume":"64","author":"Karsten","year":"1981","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"S0007125000183953_ref7","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.155.3.379"},{"key":"S0007125000183953_ref5","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.156.4.525"},{"key":"S0007125000183953_ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.1992.tb00572.x"},{"key":"S0007125000183953_ref2","first-page":"452","article-title":"Haloperidol treatment with chronically medicated residents: dose effects on clinical behaviour and reinforcement contingencies","volume":"93","author":"Aman","year":"1989","journal-title":"American Journal of Mental Retardation"},{"key":"S0007125000183953_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000183953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T19:34:05Z","timestamp":1557862445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000183953\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["S0007125000183953"],"URL":"https:\/\/doi.org\/10.1192\/bjp.166.3.374","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}